BOULDER, Colo., Sep 08, 2011 (BUSINESS WIRE) --
Array BioPharma Inc. (NASDAQ: ARRY) today announced that Karsten Witt,
M.D., has joined the Company as Vice President of Clinical Sciences.
With 26 years of experience in the field of medicine and 19 years
working in the pharmaceutical industry, Dr. Witt will lead clinical
science and drug safety activities for Array's pipeline of targeted
small molecule drugs to treat cancer and inflammatory diseases.
"Karsten brings valuable experience to Array to help us move our
proprietary pipeline to the next level," said Robert E. Conway, Chief
Executive Officer. "His expertise in advancing therapeutics for cancer
and inflammation, including the registration of Tarceva(R) (erlotinib),
will enable him to make immediate contributions to our proprietary
programs as we move into pivotal studies. I am excited to have Karsten
on the Array team."
Dr. Witt has been involved in filing six investigational new drug
applications and five new drug applications across the U.S., Europe and
Japan, including the registration of Tarceva(R) (erlotinib). From 2002
until he joined Array, Dr. Witt served as Sr. Vice President
Pharmaceutical Operations at OSI Pharmaceuticals, where he was
intimately involved in the development of small-molecule targeted
oncology therapies, including the EGFR inhibitor Tarceva(R). Dr. Witt also
served as a member of OSI's Executive Management Committee starting in
2008. From 1998 to 2001, Dr. Witt was Sr. Director of Clinical Research
& Drug Safety at NeXstar Pharmaceuticals, and continued in that position
after NeXstar's acquisition by Gilead Sciences Inc. Dr. Witt worked at
Synergen, where he assisted in setting up the company's European
Headquarters; in 1995, after Amgen purchased Synergen, he continued as a
Clinical Scientist, working primarily on inflammation programs,
including the IL-1ra program which subsequently produced Kineret(R)(anakinra).
Dr. Witt received his medical degree in 1985 from the University of
Copenhagen in Denmark and practiced medicine for six years at a
university hospital in Copenhagen.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Our proprietary drug development pipeline includes clinical candidates
that are designed to regulate therapeutically important target proteins
and are aimed at significant unmet medical needs. In addition, leading
pharmaceutical and biotechnology companies collaborate with Array to
discover and develop drug candidates across a broad range of therapeutic
areas. For more information on Array, please go to www.arraybiopharma.com.
SOURCE: Array BioPharma Inc.
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
